How much does TRYPTYR cost?

Pricing for TRYPTYR varies by insurance plan, dose, and pharmacy. Our database does not show a fixed cost because prices change faster than we can verify. For current pharmacy prices, check your insurance's formulary tier (in the prior-authorization section), use the GoodRx or Cost Plus Drugs deep links on this page, or ask your pharmacist to run a test claim. If a copay card is listed, it usually drops the out-of-pocket significantly for commercial insurance.

Does TRYPTYR need prior authorization?

TRYPTYR appears on 1 payer formulary in our database. PA requirements vary by payer — see the prior-authorization table on this page for specifics. In general, specialty and brand-name drugs are more likely to require PA than generic equivalents.

Is there a copay card or patient assistance program for TRYPTYR?

Yes — the manufacturer copay card link is available on this page. A patient assistance program is also available for qualifying patients. Eligibility typically depends on insurance type and income. Click the CTA buttons above to apply directly through the manufacturer's portal.

What is TRYPTYR used to treat?

TRYPTYR (generic: Acoltremon) is indicated for Dry Eye Syndrome. Click any condition name on this page for more detail.

Does TRYPTYR have a generic version?

The generic name for TRYPTYR is Acoltremon. Whether a generic is currently available depends on patent status — check the FDA Orange Book or ask your pharmacist. Generics are often substantially cheaper than brand-name drugs.

TRYPTYR

Generic: Acoltremon

Verified·Apr 23, 2026

Manufacturer: Azurity Pharmaceuticals
NDC: 0065-8595
RxCUI: 2716821
Route: OPHTHALMIC
ICD-10 indication: H04.129

Affordability Check

How much will you actually pay for TRYPTYR?

In 30 seconds, see every legitimate way to afford TRYPTYR — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About TRYPTYR

Triptodur is a prescription medication containing the active ingredient triptorelin, a gonadotropin-releasing hormone (GnRH) agonist. It is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). The medication works by stimulating and then desensitizing the pituitary gland, suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to reduce sex steroid levels and delay the progression of premature puberty.

Copay & patient assistance

Patient Copay Amount: As little as $30; first fill free for eligible patients through the BlinkRx trial program.
Maximum Annual Benefit Limit: Not Publicly Available
Core Eligibility Restrictions: Eligible commercially insured patients.
RxBIN, PCN, and Group numbers: Not Publicly Available

Copay card →Patient Assistance Program →

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

Cost Plus Drug Company

Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for Acoltremon.

Browse Cost Plus medications →

GoodRx

Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.

Lookup TRYPTYR →

NeedyMeds

Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.

Search for Acoltremon →

RxAssist

PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.

Search PAPs →

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for TRYPTYR. Official source: DailyMed (NLM) · Label effective Dec 18, 2025

Indications and usage

1 INDICATIONS AND USAGE TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease. TRYPTYR is a TRPM8 thermoreceptor agonist indicated for the treatment of the signs and symptoms of dry eye disease. ( 1 )

Dosage and administration

2 DOSAGE AND ADMINISTRATION Instill one drop in each eye twice daily (approximately 12 hours apart). ( 2 ) 2.1 Recommended Dosage Instill one drop in each eye twice daily (approximately 12 hours apart). 2.2 Administration Instructions Wash hands before use. The single-dose vials are to be used immediately after opening and can be used to dose both eyes. Discard the single-dose vial, including any remaining contents, immediately after use. TRYPTYR can be used concomitantly with other topical ophthalmic eye drops. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart . Contact lenses should be removed prior to the administration of TRYPTYR and may be reinserted 15 minutes following administration. If one dose is missed, treatment should continue with the next dose.

Contraindications

4 CONTRAINDICATIONS None. None. ( 4 )

Warnings and precautions

5 WARNINGS AND PRECAUTIONS To avoid the potential for eye injury and contamination, do not touch the vial tip to the eye or other surfaces. ( 5.1 ) 5.1 Potential for Eye Injury and Contamination To avoid the potential for eye injury and contamination, do not touch the vial tip to the eye or other surfaces. 5.2 Use with Contact Lenses TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.

Adverse reactions

6 ADVERSE REACTIONS The most common adverse reaction was instillation site pain (50%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9780, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients with dry eye disease, 766 patients received at least one dose of TRYPTYR in four randomized controlled clinical trials across 71 sites in the United States. The most common ocular adverse reaction observed in controlled clinical studies with TRYPTYR was instillation site pain (50%). Less than 1% of patients discontinued therapy due to burning or stinging sensation in the eyes.

Use in pregnancy

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies on TRYPTYR in pregnant women. Systemic exposure to acoltremon from ocular administration is negligible [see Clinical Pharmacology ( 12.3 )] . Intravenous administration of acoltremon to pregnant rats and rabbits during organogenesis did not produce embryofetal toxicity at 806- and 2151-fold the maximum recommended human ocular dose (MRHOD) of acoltremon on a mg/m 2 basis ( see Data ) . All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies. Data Animal Data In embryofetal developmental studies in pregnant rats and rabbits dosed by intravenous injection daily during organogenesis from gestation days 6-17 and gestation days 7-19, respectively, no maternal or fetal toxicity was observed at 806- and 2151-fold the MRHOD of acoltremon on a mg/m 2 basis.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Dry Eye Syndrome

Medicare Part D coverage

How TRYPTYR appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

8 of 5,509 plans

Most common tier

Tier 4

On 50% of covering formularies

Prior authorization required

100%

of covering formularies

Tier	Formularies on this tier	Share
Tier 1 (preferred generic)	1	50%
Tier 4 (non-preferred brand)	1	50%

Step therapy: 0% of formularies

Quantity limits: 100% of formularies

Coverage breadth: 2 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

Payer	PA	Step therapy	Copay tier
— Medicare Part D	—	—	—

Payer

Step therapy

Copay tier

—

Medicare Part D

—

Related drugs

How this page is sourced

Drug identity verified against openFDA NDC Directory.
Label text (when shown) originates from NLM DailyMed.
Copay and assistance URLs verified periodically; if you hit a broken link, tell us.